The nation of Zimbabwe has turned down a significant American healthcare agreement valued at $367m (£272m) over five years due to Washington's demand for sensitive information.
This rejection was revealed after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman later stated that the US was requesting genetic material for scientific study and commercial purposes but refused to guarantee the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued negotiations to find a deal agreeable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This development comes after a similar situation in neighbouring Kenya, where a court suspended a similar deal with the US after legal challenges were filed about the safety of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
According to reports, Sixteen African countries have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Put simply, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our citizens should a new health crisis arise."
National Interest and Global Health
He also said that the American exit from the global health body and its push of bilateral deals were undermining structures already established through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This mechanism is designed to guarantee that when a country contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our US partners on how future collaboration might be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
Medical experts said it recognised the government's concerns, but recommended that talks need to persist given that a large portion of the nation's Aids initiatives depended on international support.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group said.
This impasse highlights the continuing debate between receiving vital international aid and safeguarding a country's data in an increasingly data-driven world.